Cellular and T cell engager Immunotherapy
Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Rakesh Popat, MD, PhD
Consultant Haematologist & Associate Professor
University College London Hospitals NHS Foundation Trust
LONDON, England, United Kingdom